Angina | Medical XPRT
Articles & Whitepapers
-
First Case in Palm Springs, CA - Case Study
Circumex – Obtuse Marginal 68 yo Female Limiting Angina/Heart Failure (NYHA II) Hospice Evaluation Ongoing Non-Surgical Candidate Patient Unable to Perform Active Daily Living Duties Ejection Fraction 20% ...
-
EluNIR DES in a Challenging Case - Case Study
Background: This paper describes a challenging case of implantation of the EluNIR™ Ridaforolimus eluting elastomeric stent (Medinol Ltd.). This complex case involved a patient with a ...
News
-
XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clinical safety data from the Phase 1 dose escalation Phase 2 clinical data readouts on safety and efficacy of XC001 ...
XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease
Hemostemix Announces Pete Pavlin, P.Eng., Vice-President Operations
XyloCor Therapeutics Announces Presentation of Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina at AATS and ASGCT
Hemostemix Announces Rick Groome as Special Advisor to the CEO
Equipment & Solutions
-
Showcase
Pitavastatin Calcium
This is an antihypercholesterolemic agent characteristic of having a strong LDL cholesterol reduction effect and causing less drug-interactions. It is recognized as one of the “Strong statins” in clinical practice. In Japan, it is distributed by Kowa Company, Limited. It has been launched in 30 countries, such as the United States and countries in Latin America, Europe and Asia. It is ...